

Jakafi approved for chronic bone marrow disease

December 4 2014

(HealthDay)—Jakafi (ruxolitinib) has been approved by the U.S. Food and Drug Administration to treat polycythemia vera, a chronic disease of the bone marrow.

Jakafi is the first FDA-sanctioned drug for the disease, which occurs when too many red blood cells are produced in the bone marrow. This may lead to a swollen spleen and phlebitis, characterized by [blood clots](#) near the surface of the skin.

The disease also increases the risk of heart attack, the agency said Thursday in a news release.

Jakafi has been approved for polycythemia vera patients who cannot tolerate or have an inadequate response to other drugs. In clinical studies involving 222 people, Jakafi's most common side effects included low counts of [red blood cells](#) and blood platelets, dizziness, constipation and shingles.

The drug was first approved in 2011 to treat another [bone marrow](#) disorder, myelofibrosis.

Jakafi is marketed by Incyte Corp., based in Wilmington, Del.

More information: Visit the [FDA](#) to learn more.

Citation: Jakafi approved for chronic bone marrow disease (2014, December 4) retrieved 25 April 2024 from

<https://medicalxpress.com/news/2014-12-jakafi-chronic-bone-marrow-disease.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.